Roigas J, Wallen E S, Loening S A, Moseley P L
Clinic of Urology, Charité Medical School, Humboldt University of Berlin, Germany.
Prostate. 1998 Feb 15;34(3):195-202. doi: 10.1002/(sici)1097-0045(19980215)34:3<195::aid-pros7>3.0.co;2-h.
Hyperthermia can enhance the clinical response of chemotherapeutic agents in prostate cancer, but optimal sequencing of this combination therapy needs to be developed. Given the role of heat shock proteins (HSPs) in the development of resistance (thermotolerance) to subsequent hyperthermic stresses as well as to certain chemotherapeutics, the study of HSP regulation is important in the establishment of effective schedules in multimodal treatment strategies.
In this study we evaluated the effects of the chemotherapeutic agents cisplatin, 5-fluorouracil, and adriamycin in combination with hyperthermia. (43 degrees C, 1 h) on clonogenic survival and inducible HSP70 regulation in Dunning rat adenocarcinoma of the prostate. HSP70 was analyzed by Western blot and by measuring beta-galactosidase produced by cells stably transfected with a gene construct containing the E. coli beta-galactosidase gene driven by the Drosophila HSP70 promoter.
Colony formation assays revealed a sensitizing effect of hyperthermia when simultaneously combined with each chemotherapeutic agent, resulting in a potentiated cytotoxicity compared to subsequenced treatments. Thermotolerant cells showed a significantly better survival when treated with adriamycin alone, but also when each chemotherapeutic agent was combined with hyperthermia. This enhanced survival was correlated with inducible HSP70 accumulation. The chemotherapeutics modified the HSP70 promoter activation induced by hyperthermia, suggesting changes in the development of cellular thermotolerance.
Our data reveal synergistic cytotoxic effects of the synchronous application of chemotherapeutic agents and hyperthermia on this model of prostate cancer. Furthermore, they demonstrate that the induction of HSPs in thermotolerant cells, as measured by HSP70 induction, results in a modulation the chemotherapeutic-mediated cytotoxicity. Therefore, HSP70 is a useful marker of cellular resistance in multimodal approaches combining hyperthermia and chemotherapeutic agents in the treatment of locally advanced prostate carcinoma.
热疗可增强化疗药物对前列腺癌的临床疗效,但需要制定这种联合治疗的最佳顺序。鉴于热休克蛋白(HSPs)在对后续热应激以及某些化疗药物产生耐药性(热耐受性)过程中的作用,研究HSPs的调控对于建立多模式治疗策略中的有效方案至关重要。
在本研究中,我们评估了化疗药物顺铂、5-氟尿嘧啶和阿霉素与热疗(43℃,1小时)联合应用对Dunning大鼠前列腺腺癌克隆形成存活率和诱导型HSP70调控的影响。通过蛋白质免疫印迹法以及测量由稳定转染含有果蝇HSP70启动子驱动的大肠杆菌β-半乳糖苷酶基因构建体的细胞产生的β-半乳糖苷酶来分析HSP70。
集落形成试验显示,热疗与每种化疗药物同时联合应用时具有增敏作用,与序贯治疗相比,导致细胞毒性增强。热耐受细胞在单独用阿霉素处理时,以及每种化疗药物与热疗联合应用时,均表现出明显更好的存活率。这种存活率的提高与诱导型HSP70的积累相关。化疗药物改变了热疗诱导的HSP70启动子激活,提示细胞热耐受性发展的变化。
我们的数据揭示了化疗药物与热疗同步应用对该前列腺癌模型具有协同细胞毒性作用。此外,研究表明,通过HSP70诱导来衡量,热耐受细胞中HSPs的诱导会导致化疗介导的细胞毒性发生调节。因此,在局部晚期前列腺癌的治疗中,将热疗与化疗药物联合应用的多模式方法中,HSP70是细胞耐药性的一个有用标志物。